Buprenorphine for the treatment of acute suicidality
AssigneeCarmel-Haifa University Economic Corp. Ltd.
InventorYoram Yovell
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating acute suicidality by administration of buprenorphine are disclosed herein. An exemplary method is effected by administering to a subject determined as having acute suicidality a first therapeutically effective amount of buprenorphine, or a pharmaceutically acceptable salt thereof, whereby the administration is ceased once the subject is no longer determined as having acute suicidality. The first therapeutically effective amount is less than 0.2 mg per day. A higher therapeutically effective amount may optionally be administered if the subject is determined as not fully responsive to the first therapeutically effective amount. Unit dosage forms of buprenorphine, comprising less than 0.2 mg (e.g., 0.1 mg) buprenorphine are also disclosed.
Claims31
1-53. (canceled)
A method of treating acute suicidality in a subject in need thereof, the method being effected by administering to a subject determined as having acute suicidality a therapeutically effective amount of buprenorphine, or a pharmaceutically acceptable salt thereof, thereby treating said acute suicidality in a subject in need thereof, wherein said subject is not afflicted by a depressive disorder.
A method of treating acute suicidality in a subject in need thereof, the method comprising:
- determining a presence of acute suicidality in a subject;
- and
- administering to a subject determined as having acute suicidality about 0.1 mg of buprenorphine, or a pharmaceutically acceptable salt thereof, twice per day during a first time period, said first time period ranging from 3 days to 3 weeks;
- and
- administering to the subject about 0.2 mg of buprenorphine, or a pharmaceutically acceptable salt thereof, twice per day during a second time period, said second time period ranging from 3 days to 3 weeks;
- and
- optionally administering to the subject more than 0.4 mg/day of buprenorphine, or a pharmaceutically acceptable salt thereof, during a third time period,
- thereby treating said acute suicidality in a subject in need thereof.
A method of treating acute suicidality in a subject in need thereof, the method comprising:
- determining a presence of acute suicidality in a subject;
- and
- administering to a subject determined as having acute suicidality a first therapeutically effective amount of buprenorphine, or a pharmaceutically acceptable salt thereof, during a first time period, said first therapeutically effective amount being less than 0.2 mg per day,
- thereby treating said acute suicidality in a subject in need thereof.
A pharmaceutical composition comprising buprenorphine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, the composition being packaged in a packaging material and identified in print, in or on said packaging material, for use in the treatment of acute suicidality in a subject in need thereof.
A pharmaceutical composition unit dosage form comprising buprenorphine, or a pharmaceutically acceptable salt thereof, in an amount of less than 0.2 mg buprenorphine.
Dependencies are inferred from the claim text.